Attovia Therapeutics, Inc. (ATTO)

NASDAQ: ATTO · Real-Time Price · USD

19.86

+0.68 (3.55%)

At close: Aug 14, 2026, 4:00 PM EDT

19.56

-0.30 (-1.51%)

After-hours: Aug 14, 2026, 7:34 PM EDT

Attovia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	1.35	1.35	-
Revenue Growth	-	-	-
Cost of Revenue	58.96	54.15	33.86
Gross Profit	-57.61	-52.8	-33.86
Selling, General & Admin	13.32	14.36	7.69
Operating Expenses	13.4	14.36	7.69
Operating Income	-71.01	-67.16	-41.55
Interest & Investment Income	6.83	6.63	3.44
Other Non Operating Income (Expenses)	0.05	-0.1	-1.69
Pretax Income	-64.13	-60.63	-39.8
Net Income	-64.13	-60.63	-39.8
Net Income to Common	-64.13	-60.63	-39.8
Net Income Growth	-	-	-
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change	-	11.84%	-
EPS (Basic)	-15.89	-15.35	-11.27
EPS (Diluted)	-15.89	-15.35	-11.27
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-64.02	-61.51	-36.81
Free Cash Flow Per Share	-15.86	-15.57	-10.42
Operating Margin	-5260.00%	-4974.74%	-
Profit Margin	-4750.52%	-4490.89%	-
Free Cash Flow Margin	-4742.07%	-4556.44%	-
EBITDA	-70.11	-66.36	-41.24
D&A For EBITDA	0.9	0.8	0.31
EBIT	-71.01	-67.16	-41.55
Revenue as Reported	1.35	1.35	-

SEC Filings: 10-K · 10-Q